Evidence map›Paper›PMID 31824842›Full record

ArticleFrontiers in oncology2019

Phosphoproteomic Landscaping Identifies Non-canonical cKIT Signaling in Polycythemia Vera Erythroid Progenitors.

Giulia Federici, Lilian Varricchio, Fabrizio Martelli, Mario Falchi, Orietta Picconi, Federica Francescangeli, Paola Contavalli, Gabriella Girelli, Agostino Tafuri, Emanuel F Petricoin and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Frontiers in genetics · 2021
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Giulia FedericiIRCCS Regina Elena National Cancer Institute, Rome, Italy.
Lilian VarricchioTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Fabrizio MartelliNational Center for Preclinical and Clinical Research and Evaluation of Pharmaceutical Drugs, Istituto Superiore di Sanità, Rome, Italy.
Mario FalchiNational HIV/AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Orietta PicconiNational HIV/AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Federica FrancescangeliOncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Paola ContavalliOncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Gabriella GirelliImmunohematology and Transfusion Medicine Unit, "La Sapienza" University of Rome, Rome, Italy.
Agostino TafuriSant'Andrea Hospital-La Sapienza, Department of Clinic and Molecular Medicine "La Sapienza" University of Rome, Rome, Italy.
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, United States.
Maria MazzariniDepartment of Biomedical and Neuromotorial Sciences, Alma Mater University, Bologna, Italy.
Ann ZeunerOncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Anna Rita MigliaccioMyeloproliferative Neoplasm Research Consortium, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Istituto Superiore di Sanità · ITIcahn School of Medicine at Mount Sinai · USSapienza University of Rome · ITGeorge Mason University · USIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Bologna · IT

Funding

Tissue BankP01CA108671 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Ronald Hoffman · 2006 to 2026
$82.0M
Generation of cultured RBCs with rare phenotypes for transfusion from sources usually discarded during regular blood donationsR01HL134684 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BIEKER, JAMES J, MIGLIACCIO, ANNA RITA F · 2018 to 2021
$1.7M
NCI NIH HHS P01 CA108671NHLBI NIH HHS R01 HL134684
6 · The paper itself

Abstract

Although stem cell factor (SCF)/cKIT interaction plays key functions in erythropoiesis, cKIT signaling in human erythroid cells is still poorly defined. To provide new insights into cKIT-mediated erythroid expansion in development and disease, we performed phosphoproteomic profiling of primary erythroid progenitors from adult blood (AB), cord blood (CB), and Polycythemia Vera (PV) at steady-state and upon SCF stimulation. While AB and CB, respectively, activated transient or sustained canonical cKIT-signaling, PV showed a non-canonical signaling including increased mTOR and ERK1 and decreased DEPTOR. Accordingly, screening of FDA-approved compounds showed increased PV sensitivity to JAK, cKIT, and MEK inhibitors. Moreover, differently from AB and CB, in PV the mature 145kDa-cKIT constitutively associated with the tetraspanin CD63 and was not endocytosed upon SCF stimulation, contributing to unrestrained cKIT signaling. These results identify a clinically exploitable variegation of cKIT signaling/metabolism that may contribute to the great erythroid output occurring during development and in PV.

Indexed as

cKITerythroid progenitorserythropoiesispolycythemia verastem cell factor

Identifiers

PMID31824842
PMCPMC6883719
OpenAlexW2991197354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.